Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2004

Open Access 01-12-2004 | Editorial

Open Access gains attention in scholar communication

Authors: Paul J Chiao, Christian Schmidt

Published in: Molecular Cancer | Issue 1/2004

Login to get access

Excerpt

Open Access is one of the attempts to maximize the exchange of information, and therefore benefits the scholar communication [1]. Molecular Cancer offers Open Access to all of its content, thereby providing a platform to present information to specialists and the public in order to further promote free exchange of ideas, concepts and findings in all fields of cancer-related biomedical science. All the published articles in the journal are determined by the peer review process. …
Literature
1.
Salva U: Open access already exists. Science. 2004, 303: 1467-
2.
Lawrence S: Free online availability substantially increases a paper's impact. Nature. 2001, 411: 521- 10.1038/35079151CrossRefPubMed
3.
4.
Deora AB, Schmidt C, Sclabas GM: First anniversary of Molecular Cancer: achievements and future goals. Mol Cancer. 2003, 2: 26- 10.1186/1476-4598-2-26PubMedCentralCrossRef
Metadata
Title
Open Access gains attention in scholar communication
Authors
Paul J Chiao
Christian Schmidt
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2004
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-3-23

Other articles of this Issue 1/2004

Molecular Cancer 1/2004 Go to the issue

Research

Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells

Short communication

Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression?

Research

Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities

Research

Scambio, a novel guanine nucleotide exchange factor for Rho

Research

RNA-binding proteins to assess gene expression states of co-cultivated cells in response to tumor cells

Research

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits